INS-101

INS-101 is an investigational **gene therapy** being developed by InnoSkel for **spondyloepiphyseal dysplasia congenita** and related **type II collagen disorders** in pediatric patients. Public descriptions indicate it is designed for **systemic delivery** to restore **COL2A1** function in growth plates, with the therapeutic goal of improving bone growth and preventing skeletal and extraskeletal complications associated with defective type II collagen. Available public information suggests the program remained **preclinical** while InnoSkel used natural-history and observational studies to support future interventional development; detailed construct-level information such as vector design, promoter, transgene cassette, and exact administration regimen has not been clearly disclosed in the sources reviewed.